Cargando…
Impact of pediatric hypophosphatasia on behavioral health and quality of life
BACKGROUND: Hypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function mutations in the ALPL gene encoding tissue nonspecific alkaline phosphatase. It is characterized by defective bone mineralization associated with low alkaline phosphatase activity. Clinical features of pediatric...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881480/ https://www.ncbi.nlm.nih.gov/pubmed/33579333 http://dx.doi.org/10.1186/s13023-021-01722-7 |
_version_ | 1783650886862503936 |
---|---|
author | Pierpont, Elizabeth I. Simmons, Jill H. Spurlock, Katherine J. Shanley, Ryan Sarafoglou, Kyriakie M. |
author_facet | Pierpont, Elizabeth I. Simmons, Jill H. Spurlock, Katherine J. Shanley, Ryan Sarafoglou, Kyriakie M. |
author_sort | Pierpont, Elizabeth I. |
collection | PubMed |
description | BACKGROUND: Hypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function mutations in the ALPL gene encoding tissue nonspecific alkaline phosphatase. It is characterized by defective bone mineralization associated with low alkaline phosphatase activity. Clinical features of pediatric HPP are highly variable, and can include premature loss of teeth, musculoskeletal problems, and impaired mobility. The effects of pediatric HPP on sleep, mood, regulation of attention and behavior, and other aspects of behavioral health have not been comprehensively studied. METHODS: Parents of 30 children with HPP (14 females, 16 males) between the ages of 3 and 16 years (mean age = 8.0 years) enrolled in this cross-sectional survey-based study. Molecular genetic and biochemical testing as well as clinical records were reviewed to verify diagnosis of HPP. The cohort included 15 patients with a more clinically severe presentation of HPP who had received treatment with enzyme replacement therapy (asfotase alfa) and 15 children with less severe HPP who were treatment-naïve. Parents provided information regarding psychopathological comorbidity, emotional and behavioral well-being, and quality of life. RESULTS: Clinically significant behavioral health challenges were evident in 67% of children with HPP. The most common behavioral findings included sleep disturbance and symptoms of attention deficit hyperactivity disorder (ADHD), each of which were observed ≥ 50% of individuals. Sleep disturbance, pain interference, poor behavioral regulation, and mood/anxiety symptoms were associated with reduced physical and psychosocial quality of life. Behavioral concerns were evident among children with HPP receiving asfotase alfa treatment as well as among children with clinically less severe disease who had not initiated therapy. Although most children in the cohort (77%) had age-typical development of adaptive skills, emotional and behavioral challenges were associated with weaker adaptive function. CONCLUSIONS: Children with HPP are at increased risk for ADHD symptoms and other behavioral health challenges. There is likely an under-recognition of these findings in clinical practice. |
format | Online Article Text |
id | pubmed-7881480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78814802021-02-17 Impact of pediatric hypophosphatasia on behavioral health and quality of life Pierpont, Elizabeth I. Simmons, Jill H. Spurlock, Katherine J. Shanley, Ryan Sarafoglou, Kyriakie M. Orphanet J Rare Dis Research BACKGROUND: Hypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function mutations in the ALPL gene encoding tissue nonspecific alkaline phosphatase. It is characterized by defective bone mineralization associated with low alkaline phosphatase activity. Clinical features of pediatric HPP are highly variable, and can include premature loss of teeth, musculoskeletal problems, and impaired mobility. The effects of pediatric HPP on sleep, mood, regulation of attention and behavior, and other aspects of behavioral health have not been comprehensively studied. METHODS: Parents of 30 children with HPP (14 females, 16 males) between the ages of 3 and 16 years (mean age = 8.0 years) enrolled in this cross-sectional survey-based study. Molecular genetic and biochemical testing as well as clinical records were reviewed to verify diagnosis of HPP. The cohort included 15 patients with a more clinically severe presentation of HPP who had received treatment with enzyme replacement therapy (asfotase alfa) and 15 children with less severe HPP who were treatment-naïve. Parents provided information regarding psychopathological comorbidity, emotional and behavioral well-being, and quality of life. RESULTS: Clinically significant behavioral health challenges were evident in 67% of children with HPP. The most common behavioral findings included sleep disturbance and symptoms of attention deficit hyperactivity disorder (ADHD), each of which were observed ≥ 50% of individuals. Sleep disturbance, pain interference, poor behavioral regulation, and mood/anxiety symptoms were associated with reduced physical and psychosocial quality of life. Behavioral concerns were evident among children with HPP receiving asfotase alfa treatment as well as among children with clinically less severe disease who had not initiated therapy. Although most children in the cohort (77%) had age-typical development of adaptive skills, emotional and behavioral challenges were associated with weaker adaptive function. CONCLUSIONS: Children with HPP are at increased risk for ADHD symptoms and other behavioral health challenges. There is likely an under-recognition of these findings in clinical practice. BioMed Central 2021-02-12 /pmc/articles/PMC7881480/ /pubmed/33579333 http://dx.doi.org/10.1186/s13023-021-01722-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Pierpont, Elizabeth I. Simmons, Jill H. Spurlock, Katherine J. Shanley, Ryan Sarafoglou, Kyriakie M. Impact of pediatric hypophosphatasia on behavioral health and quality of life |
title | Impact of pediatric hypophosphatasia on behavioral health and quality of life |
title_full | Impact of pediatric hypophosphatasia on behavioral health and quality of life |
title_fullStr | Impact of pediatric hypophosphatasia on behavioral health and quality of life |
title_full_unstemmed | Impact of pediatric hypophosphatasia on behavioral health and quality of life |
title_short | Impact of pediatric hypophosphatasia on behavioral health and quality of life |
title_sort | impact of pediatric hypophosphatasia on behavioral health and quality of life |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881480/ https://www.ncbi.nlm.nih.gov/pubmed/33579333 http://dx.doi.org/10.1186/s13023-021-01722-7 |
work_keys_str_mv | AT pierpontelizabethi impactofpediatrichypophosphatasiaonbehavioralhealthandqualityoflife AT simmonsjillh impactofpediatrichypophosphatasiaonbehavioralhealthandqualityoflife AT spurlockkatherinej impactofpediatrichypophosphatasiaonbehavioralhealthandqualityoflife AT shanleyryan impactofpediatrichypophosphatasiaonbehavioralhealthandqualityoflife AT sarafogloukyriakiem impactofpediatrichypophosphatasiaonbehavioralhealthandqualityoflife |